UK Biobank (core renewal)

英国生物库得到了惠康信托、国家健康研究所、医学研究理事会、英国心脏基金会和英国癌症研究中心的支持。这份记录中的数字代表了医学研究理事会的资金贡献，另外还有一些额外的UKRI基础设施基金。英国生物库是一项前瞻性研究，对象是招募时年龄在40-69岁的500,000名男性和女性(2006-10)。这项研究收集了参与者的大量表型和基因细节，包括问卷调查、体格测量、样本分析、加速度量计、成像、全基因组基因分型和对一系列与健康相关的结果的长期纵向跟踪的数据。该资源定期增加额外的数据，可供世界各地的学术或商业研究人员用于任何类型的符合公众利益的与健康有关的研究。它的建立主要是为了进行前瞻性研究，调查长期跟踪期间发生的各种暴露与健康后果的相关性。目前正在对资源中越来越多的常见疾病的事件进行识别和裁决，这将支持对其决定因素进行广泛而有力的研究，并且随着未来5-10年期间不同类型的事件数量的增加，可以可靠研究的疾病的范围将会扩大。因此，英国生物库为来自世界各地的研究人员提供了更多机会，更好地了解疾病的早期阶段及其诊断，并可以支持针对中老年疾病的新疗法的开发。

UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.